856 related articles for article (PubMed ID: 19804684)
1. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Cahill K; Stevens S; Perera R; Lancaster T
Cochrane Database Syst Rev; 2013 May; 2013(5):CD009329. PubMed ID: 23728690
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of varenicline for smoking cessation.
Keiding H
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
[TBL] [Abstract][Full Text] [Related]
7. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM; Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
9. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
10. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
11. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
12. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
13. Varenicline: a first-line treatment option for smoking cessation.
Garrison GD; Dugan SE
Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
16. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
Xenakis JG; Kinter ET; Ishak KJ; Ward AJ; Marton JP; Willke RJ; Davies S; Caro JJ
Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
[TBL] [Abstract][Full Text] [Related]
17. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
[TBL] [Abstract][Full Text] [Related]
18. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
[TBL] [Abstract][Full Text] [Related]
19. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.
Jackson KC; Nahoopii R; Said Q; Dirani R; Brixner D
J Occup Environ Med; 2007 Apr; 49(4):453-60. PubMed ID: 17426529
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
Taylor M; Leonardi-Bee J; Agboola S; McNeill A; Coleman T
Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
